Oncology Researchers Dr. Alan Sandler and Dr. James Cassidy Join Medical Advisory Board of Oncology CRO Medelis

Share Article

Medelis, an oncology CRO providing contract research services for preclinical, phase I, phase II, and phase III oncology clinical trials in the US and Europe, has added two of the world's leading oncology researchers, Dr. Alan Sandler of Portland, Oregon and Dr. James Cassidy of Glasgow, Scotland, to its medical advisory board.

Medelis, Inc., a full-service oncology contract research organization (CRO) providing drug development services in the US and Europe, today announced the addition of two of the world's leading oncology researchers, Dr. Alan Sandler of Portland, Oregon and Dr. James Cassidy of Glasgow, Scotland, to its medical advisory board.

Alan Sandler, M.D. is a Professor of Medicine at Oregon Health & Science University. Board-certified in Medical Oncology and Internal Medicine, he specializes in cancer and blood disorders with a sub-specialty in lung cancer. He is widely considered a key opinion leader in the development of targeted therapies in the treatment of thoracic malignancies.

James Cassidy, MBChB, MD, MSc, FRCP is a leading researcher in anti-sickness compounds and innovative approaches to drug-resistant tumors. He is a Professor of Oncology and heads the Medical Oncology Department and the Division of Cancer Sciences & Molecular Pathology at the University of Glasgow, Scotland.

"Medelis is very privileged to add Dr. Cassidy and Dr. Sandler to our distinguished group of expert advisors," said Bob Bosserman, Medelis' president & CEO. "They strengthen our ability to provide clients with cutting-edge expertise and assistance in the development and advancement of personalized therapies, which will ultimately help improve the treatment options for clinicians. They also further strengthen our relationship with the clinical research community that directly cares for cancer patients and closely understands their needs."

"Both of these physician/researchers can now bring their clinical experience to bear on the unique study design and management issues that our biotechnology and pharmaceutical clients face in the oncology drug development process," Bosserman added.

>> About Alan Sandler, M.D.

Alan Sandler, M.D. is a Professor of Medicine in the Division of Hematology & Medical Oncology, Department of Medicine, at Oregon Health & Science University in Portland, Oregon where he also serves as the Division Chief of the Hematology & Medical Oncology Division, and is the DeArmond Chair for Clinical Cancer Research. He is board certified in Internal Medicine and Medical Oncology and specializes in cancer and blood disorders with a special interest in lung cancer.

Dr. Sandler is a member of the American Society of Clinical Oncology, and the Eastern Cooperative Oncology Group, where he serves as the Co-Chair of the Thoracic Committee. He is principal investigator or co-principal investigator of several therapeutic clinical trials that evaluate the activity of chemotherapeutic agents and/or combined-modality therapies in both small and non-small cell lung cancer as well as sarcoma.

>> About James Cassidy, MBChB, MD, MSc, FRCP

Dr. James Cassidy is a Professor of Oncology and heads the Medical Oncology Department and the Division of Cancer Sciences & Molecular Pathology at the University of Glasgow, Scotland, responsible for a variety of both laboratory and clinical services programs aimed at covering all modalities and types of malignancy. In the laboratory, Dr. Cassidy heads the Centre for Oncology and Applied Pharmacology (COAP) and has his own Cancer Research UK (CRUK) lab exploring methods for gene and drug delivery. He also heads the Glasgow Experimental Cancer Medicine Centre (ECMC), focused on Good Laboratory Practice (GLP) quality assured assessments of molecular markers, pharmacodynamics and pharmacokinetics of novel agents at the clinical /lab translational interface.

On the clinical side, Dr. Cassidy runs a service for colorectal cancer patients, with a major commitment to early phase clinical studies of innovative therapies. He also heads the clinical trials CACTUS, WoSCRN and is director of the CRUK Beatson Cancer Trials unit. He has been Chief investigator of several large scale RCTs in colorectal cancer over the last decade.

>> About Medelis, Inc.

Medelis, Inc. is an oncology CRO providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, team physicians and clinical trial management physicians, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials.

Medelis is privately-held with US offices in Phoenix, Nashville, Boston and Reno. Medelis Europe is headquartered in Port Vendres, France.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Bob Bosserman
Medelis, Inc.
602-840-1101 ext. 85016
Email >
Visit website